The post Auto Draft appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com

Better adherence to a Mediterranean-like diet may help prevent disability worsening in people with early multiple sclerosis (MS), in part by slowing biological aging, according to data from a new study. The findings suggest that diet, biological age, and disability are closely connected and that lifestyle changes could potentially influence long-term disease outcomes. “Biological aging…

The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people with primary progressive multiple sclerosis (PPMS), failing to meet the main goal and several key secondary goals of the Phase 3 PERSEUS trial. It did, however, show signs of benefit on MRI scans, including fewer new…

Tweet A couple of years ago we were awakened to the prospect of EBV being the cause of multiple sclerosis, at least part of the causal route. It was based on two papers one that it was shown that people who develop MS were infected with Epstein Bar Virus before, maybe years, they got MS….

The complement system — part of the immune system that helps defend against infections — may play a key role in age-related disease progression in multiple sclerosis (MS), according to findings from a mouse study. In fact, blocking a complement protein called C3 reduced disease severity in older mice but not in younger ones, the…

For the average person, catching a cold is a minor inconvenience—a few days of tissues and cough syrup before bouncing back to work. But for those of us living with multiple sclerosis (MS), the narrative is often drastically different. We … Continue reading → Source: blog.mymsaa.org

The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the first in more than 10 years to slow disability…

The month of February may be a shorter month, but it has left a few empty places in my heart. Of course, despite a couple of heartbreaking events that occurred during February, a few great things also happened. It is, as we have always heard, that you cannot have sunshine without darkness, and you cannot experience good without the bad. These…

Despite this, I often refer to MS as a lonely illness. With a vast array of associated neurological and non-neurological symptoms spread over four different types of MS, it will be exponentially difficult to find someone who has the exact same symptoms with a similarly matching field of outcomes. Source: irelandms.com